fluoromisonidazole has been researched along with Astrocytoma, Grade IV in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 13 (56.52) | 24.3611 |
| 2020's | 5 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| Qin, J; Tang, Y; Wang, B | 1 |
| Akasaki, Y; Fukasawa, N; Miyake, K; Murayama, Y; Ogawa, D; Shimoda, M; Suzuki, K; Suzuki, T; Takei, J; Tanaka, T; Yamamoto, Y | 1 |
| Abdo, RA; Bentourkia, M; Fernandez, P; Lamare, F | 1 |
| Furuya, S; Hirata, K; Kobayashi, H; Kobayashi, K; Kudo, K; Kuge, Y; Magota, K; Manabe, O; Shiga, T; Tamaki, N; Terasaka, S; Toyonaga, T; Yamaguchi, S | 1 |
| Brenner, AJ; Clarke, GD; Floyd, JR; Fox, PT; Huang, S; Hyun, H; Jerabek, PA; Lee, EQ; Michalek, JE; Muzi, M; Reardon, DA; Schmainda, KM; Wen, PY | 1 |
| Bernaudin, M; Berro, DH; Chakhoyan, A; Collet, S; Constans, JM; Derlon, JM; Guillamo, JS; Guillouet, S; Hatt, M; Lechapt-Zalcman, E; Perrio, C; Valable, S; Visvikis, D | 1 |
| Barré, L; Bernaudin, M; Chakhoyan, A; Collet, S; Constans, JM; Delcroix, N; Guillamo, JS; Kauffmann, F; Lechapt-Zalcman, E; MacKenzie, ET; Petit, E; Touzani, O; Valable, S | 1 |
| Andronesi, OC; Barboriak, D; Ellingson, B; Fink, J; Gerstner, ER; Greco, E; Hanna, L; Kim, D; Kostakoglu, L; Mankoff, D; Mintz, A; Muzi, M; Prah, M; Ratai, EM; Richards, T; Schmainda, K; Sorensen, G; Zhang, Z | 1 |
| Hirata, K; Houkin, K; Kobayashi, H; Shiga, T; Terasaka, S; Yamaguchi, S | 1 |
| Hamaji, M; Harada, H; Kimura, H; Koizumi, K; Koyasu, S; Nakamoto, Y; Nobashi, T; Sano, K; Togashi, K; Tsuji, Y | 1 |
| Barboriak, DP; Eikman, EA; Ellingson, BM; Fink, JR; Gerstner, ER; Greco, E; Hanna, L; Kostakoglu, L; Mankoff, DA; Mintz, A; Muzi, M; Prah, M; Ratai, EM; Schmainda, KM; Sorensen, AG; Zhang, Z | 1 |
| Anzellotti, AI; Frank, JE; Hillesheim, DA; Khachaturian, MH; Merrill, JR; Yuan, H | 1 |
| Hattori, N; Hirata, K; Ito, YM; Kobayashi, H; Kobayashi, K; Kuge, Y; Manabe, O; Shiga, T; Tamaki, N; Tanaka, S; Terasaka, S; Toyonaga, T; Watanabe, S; Yamaguchi, S | 1 |
| Adamsen, TC; Chakraborty, G; Harpold, HL; Krohn, KA; Muzi, M; Rockne, R; Spence, AM; Swanson, KR; Wang, CH | 1 |
| Alvord, EC; Chakraborty, G; Hadley, J; Krohn, KA; Muzi, M; Rockne, R; Spence, AM; Swanson, KR; Szeto, MD | 1 |
| Kawai, N; Kudomi, N; Maeda, Y; Miyake, K; Nishiyama, Y; Okada, M; Tamiya, T; Yamamoto, Y | 1 |
| Alessio, AM; Alvord, EC; Anderson, AR; Chakraborty, G; Champley, K; Claridge, J; Gu, S; Kinahan, PE; Krohn, KA; Muzi, M; Rockne, R; Spence, AM; Swanson, KR | 1 |
| De Clermont, H; Fernandez, P; Huchet, A; Lamare, F; Rivière, A | 1 |
| Aoyama, H; Hirata, K; Houkin, K; Kobayashi, H; Murata, J; Narita, T; Onodera, S; Shiga, T; Tanaka, S; Terasaka, S | 1 |
| Hattori, N; Hirata, K; Houkin, K; Kobayashi, H; Kuge, Y; Magota, K; Shiga, T; Tamaki, N; Tanaka, S; Terasaka, S; Yamaguchi, S | 1 |
| Boerman, OC; Bussink, J; Kaanders, JH; Laverman, P; Lok, J; Oyen, WJ; Philippens, M; Troost, EG; van der Kogel, AJ | 1 |
| Adamsen, TC; Krohn, KA; Link, JM; Muzi, M; O'Sullivan, F; Rajendran, JG; Rockhill, JK; Rostomily, RC; Silbergeld, DL; Spence, AM; Swanson, KR; Swanson, PE; Yagle, KJ | 1 |
| Budinger, TF; Gilbert, JC; Mathis, CA; Prados, MD; Valk, PE | 1 |
1 review(s) available for fluoromisonidazole and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Usefulness of FMISO-PET for glioma analysis.
Topics: Adult; Animals; Brain Neoplasms; Diagnosis, Differential; Fluorine Radioisotopes; Glioblastoma; Glioma; Humans; Misonidazole; Oxygen; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results | 2013 |
4 trial(s) available for fluoromisonidazole and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Analysis of hypoxia in human glioblastoma tumors with dynamic 18F-FMISO PET imaging.
Topics: Brain Neoplasms; Carotid Artery, Common; Glioblastoma; Humans; Image Processing, Computer-Assisted; Misonidazole; Positron-Emission Tomography; Time Factors; Tumor Burden; Tumor Hypoxia | 2019 |
ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.
Topics: Aged; Brain; Brain Neoplasms; Female; Glioblastoma; Humans; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Prognosis; Proton Magnetic Resonance Spectroscopy; Radiopharmaceuticals; ROC Curve; Tumor Hypoxia | 2018 |
Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Cell Hypoxia; Female; Glioblastoma; Humans; Male; Methionine; Middle Aged; Misonidazole; Positron-Emission Tomography; Tumor Burden | 2011 |
¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.
Topics: Adult; Aged; Anaplasia; Biological Transport; Brain Neoplasms; Diagnosis, Differential; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Misonidazole; Neoplasm Grading; Positron-Emission Tomography | 2012 |
18 other study(ies) available for fluoromisonidazole and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Regional 18F-fluoromisonidazole PET images generated from multiple advanced MR images using neural networks in glioblastoma.
Topics: Bayes Theorem; Glioblastoma; Humans; Misonidazole; Neural Networks, Computer; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2022 |
Topics: B7-H1 Antigen; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Immunohistochemistry; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Tumor Microenvironment | 2023 |
Influence of the scan time point when assessing hypoxia in
Topics: Glioblastoma; Humans; Hypoxia; Misonidazole; Positron-Emission Tomography; Radiopharmaceuticals | 2020 |
Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and
Topics: Adult; Aged; Bevacizumab; Biomarkers, Pharmacological; Brain Neoplasms; Cerebral Blood Volume; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Neoplasm Recurrence, Local; Positron-Emission Tomography; Progression-Free Survival; Tumor Hypoxia; Young Adult | 2021 |
Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI,
Topics: Adult; Glioblastoma; Humans; Middle Aged; Misonidazole; Positron-Emission Tomography | 2021 |
FMISO-PET-derived brain oxygen tension maps: application to glioblastoma and less aggressive gliomas.
Topics: Adult; Aged; Brain Mapping; Brain Neoplasms; Female; Glioblastoma; Gray Matter; Humans; Hypoxia, Brain; Male; Middle Aged; Misonidazole; Perfusion Imaging; Positron Emission Tomography Computed Tomography; Prospective Studies; ROC Curve; White Matter | 2017 |
Evaluation of Tumor-associated Stroma and Its Relationship with Tumor Hypoxia Using Dynamic Contrast-enhanced CT and (18)F Misonidazole PET in Murine Tumor Models.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Female; Glioblastoma; Hypoxia; Immunohistochemistry; Mice; Misonidazole; Pancreatic Neoplasms; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiographic Image Interpretation, Computer-Assisted; Tomography, X-Ray Computed | 2016 |
ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.
Topics: Adult; Aged; Biomarkers; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Neovascularization, Pathologic; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tumor Hypoxia | 2016 |
Automated PET Radiotracer Manufacture on the BG75 System and Imaging Validation Studies of [18F]fluoromisonidazole ([18F]FMISO).
Topics: Animals; Autoradiography; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Chromatography, High Pressure Liquid; Glioblastoma; Humans; Mice; Misonidazole; Positron Emission Tomography Computed Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Tissue Distribution | 2016 |
Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.
Topics: Adult; Aged; Blood Glucose; Brain Neoplasms; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Glioblastoma; Glycolysis; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Oxygen; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2017 |
Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas.
Topics: Adult; Aged; Female; Gadolinium; Glioblastoma; Humans; Hypoxia; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Neovascularization, Pathologic; Positron-Emission Tomography; Prognosis; Survival Analysis; Tumor Burden | 2009 |
Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas.
Topics: Adult; Brain Neoplasms; Cell Division; Computer Simulation; Contrast Media; Female; Fluorine Radioisotopes; Gadolinium; Glioblastoma; Humans; Image Enhancement; Magnetic Resonance Imaging; Middle Aged; Misonidazole; Neoplasm Invasiveness; Positron-Emission Tomography | 2009 |
Applying a patient-specific bio-mathematical model of glioma growth to develop virtual [18F]-FMISO-PET images.
Topics: Adult; Brain Neoplasms; Cell Proliferation; Computer Simulation; Fluorine Radioisotopes; Glioblastoma; Glioma; Humans; Hypoxia; Image Interpretation, Computer-Assisted; Male; Mathematical Concepts; Misonidazole; Models, Biological; Necrosis; Neoplasm Invasiveness; Neovascularization, Pathologic; Positron-Emission Tomography; Precision Medicine; Radiopharmaceuticals; User-Computer Interface | 2012 |
Lack of concordance between the F-18 fluoromisonidazole PET and the F-18 FDG PET in human glioblastoma.
Topics: Fluorodeoxyglucose F18; Glioblastoma; Humans; Male; Middle Aged; Misonidazole; Positron-Emission Tomography | 2011 |
Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports.
Topics: Aged; Antineoplastic Agents, Alkylating; Cell Hypoxia; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Male; Middle Aged; Misonidazole; Oxygen; Positron-Emission Tomography; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome | 2012 |
Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.
Topics: Animals; Autoradiography; Carcinoma, Squamous Cell; Cell Hypoxia; Fluorine Radioisotopes; Glioblastoma; Head and Neck Neoplasms; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Misonidazole; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Radionuclide Imaging | 2006 |
Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival.
Topics: Adult; Aged; Brain Neoplasms; Cell Hypoxia; Disease Progression; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Misonidazole; Positron-Emission Tomography; Regression Analysis | 2008 |
Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole.
Topics: Adult; Astrocytoma; Brain Neoplasms; Cell Hypoxia; Fluorine Radioisotopes; Glioblastoma; Humans; Male; Middle Aged; Misonidazole; Tomography, Emission-Computed | 1992 |